SightfileU.S. market data from official filings

Akari Therapeutics PLC ADR (AKTX)

Name: Akari Therapeutics PLC ADR (AKTX) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001541157 · EDGAR filings · Updated 2026-07-17

Akari Therapeutics PLC ADR (AKTX) has 6 institutional managers reporting positions valued at $307.3K per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.

Institutional managers

Reported 13F value

$307.3K

Insider activity

14 trans.

$56.7K net buying

Data flags

2 active

from SEC filings

Latest updates

2026-07-17 — Insider transaction reported (Form 4)
2026-07-13 — EFFECT filed
2026-07-10 — S-3/A filed
2026-07-08 — S-3/A filed
2026-07-07 — EFFECT filed
2026-07-02 — Current report (8-K) filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, Akari Therapeutics PLC ADR has 6 institutional holders.

Insider activity

Insiders reported 14 transactions (7 buys, 0 sells) across 3 reporting insiders, with a net reported value of $56.7K.

Data flags from SEC filings

Active substantial-doubt (going concern) disclosure per the filings, most recently filed 2026-05-19 (recurring since 2020-03-31) — source filing. The authoritative details are those stated in the filing itself.

Active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), most recently filed 2025-11-26 (recurring since 2024-04-11) — source filing. The authoritative details are those stated in the filing itself.

Related companies

KAIROS PHARMA LTD (KAPA) · NexGel Inc (NXGL) · Soligenix Inc (SNGX) · Nuwellis Inc (NUWE) · MANGOCEUTICALS INC (MGRX) · KALA BIO Inc (KALA)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-17.